AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.15
+0.05 (+1.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.10
Open3.10
Bid3.05 x 800
Ask4.00 x 1800
Day's Range3.10 - 3.20
52 Week Range2.05 - 6.45
Volume91,079
Avg. Volume174,895
Market Cap80.909M
Beta-0.28
PE Ratio (TTM)N/A
EPS (TTM)-1.06
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s Association International Conference (AAIC) on July 23, 2018 in Chicago, IL. AXS-05 is a novel, oral, investigational medicine consisting of dextromethorphan and bupropion, in late-stage development for the treatment of agitation associated with Alzheimer’s disease. The presentation will highlight data correlating AXS-05 drug levels from Phase 1 trials to neurotransmitter receptor activation and to improvements in agitation symptoms in patients with Alzheimer’s disease.

  • GlobeNewswirelast month

    Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in the ASCEND (Assessing Clinical Episodes in Depression) study, a Phase 2 randomized, controlled trial of AXS-05 in major depressive disorder (MDD). AXS-05 is a novel, oral, glutamatergic and monoaminergic investigational medicine consisting of dextromethorphan and bupropion. Topline results from the ASCEND trial are expected in the second half of 2018.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Phase 1 pharmacokinetic and mechanism of action data and analyses for AXS-05, its novel glutamatergic and monoaminergic product candidate, will be presented at the 2018 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) on May 31, 2018 in Miami, FL. Analyses will be presented demonstrating similarities between AXS-05 and the potent and fast-acting antidepressant ketamine, based on mechanisms of action and functional animal data. Data from a Phase 1 pharmacokinetic trial of AXS-05 will also be presented along with analyses showing attainment of drug levels that target CNS receptors relevant to neuropsychiatric disorders.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Present at the 2018 BIO International Convention

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at the 2018 Biotechnology Innovation Organization (BIO) International Convention on June 5, 2018 at 1:45 PM Eastern Time. The convention will be held at the Boston Convention and Exhibition Center in Boston, MA. A live webcast of the event can be viewed on the company’s website at www.axsome.com.

  • Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?
    Simply Wall St.2 months ago

    Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?

    Leading Axsome Therapeutics Inc (NASDAQ:AXSM) as the CEO, Herriot Tabuteau took the company to a valuation of US$83.04M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Associated Press2 months ago

    Axsome: 1Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 19 cents. The company's shares closed at $3.35. A year ago, they were trading at $3.90. _____ This story was generated by Automated ...

  • GlobeNewswire2 months ago

    Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

    NEW YORK, May 08, 2018-- Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today reported financial ...

  • ACCESSWIRE2 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 8, 2018 at 8:00 AM Eastern Time. ...

  • GlobeNewswire3 months ago

    Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 (bupropion and dextromethorphan), its novel glutamatergic and monoaminergic product candidate, at the 2018 Annual Meeting of the American Psychiatric Association on May 8, 2018 in New York, NY. The poster will highlight the anti-inflammatory properties of AXS-05, the potential role of inflammation in depressive disorders, and pharmacokinetic and pharmacodynamic analyses supporting the development of AXS-05 in treatment resistant depression. The current status of the Company’s ongoing Phase 3 trial of AXS-05 in treatment resistant depression, and ongoing Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease will also be presented.

  • GlobeNewswire3 months ago

    Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

    Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time. NEW YORK, May 01, 2018-- Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel ...

  • GlobeNewswire3 months ago

    Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

    Independent Data Monitoring Committee recommends trial continuation. Second interim analysis anticipated second half of 2018 for efficacy. NEW YORK, April 26, 2018-- Axsome Therapeutics, Inc., a clinical-stage ...

  • ACCESSWIRE3 months ago

    Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Axsome Therapeutics, Inc. (NASDAQ: AXSM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXSM as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has enrolled first patient into a Phase-2 trial assessing AXS-05 for smoking cessation treatment.

  • GlobeNewswire3 months ago

    Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence

    NEW YORK, April 24, 2018-- Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, is hosting a research ...

  • GlobeNewswire3 months ago

    Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the enrollment of the first patient into a Phase 2 trial of AXS-05 for smoking cessation treatment. The trial is being conducted under a research collaboration between Duke University and Axsome Therapeutics. Duke University is recognized as one of the world’s leading centers for smoking cessation research.

  • Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
    Simply Wall St.3 months ago

    Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?

    In this analysis, my focus will be on developing a perspective on Axsome Therapeutics Inc’s (NASDAQ:AXSM) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...

  • Associated Press4 months ago

    Axsome reports 4Q loss

    On a per-share basis, the New York-based company said it had a loss of 31 cents. Losses, adjusted for non-recurring costs, were 28 cents per share. For the year, the company reported that its loss widened ...

  • ACCESSWIRE4 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 8:00 AM Eastern ...